Kinnate Biopharma is targeting known oncogenic drivers, says it is well-funded

Kinnate Biopharma chief financial officer Neha Krishnamohan joined Proactive with details of the two lead candidates in clinical-stage oncology company’s pipeline program – KIN-2787 and KIN-3248 – as it focuses its efforts on known oncogenic drivers where there are no approved targeted drugs, and to overcome the limitations of marketed cancer therapies.

Krishnamohan noted that Kinnate is well-funded, with a cash runway of $302.4 million as of March 31, 2022, which is expected to fund current operations, including initiation of multiple registrational studies, into early 2024.

© 2022 The Latest StockMarket News and Interviews